This week's arrest of hedge fund manager Murray Huberfeld for an alleged kickback scheme with New York City's correction officers union didn't surprise one private eye. Financial fraud investigations have increased dramatically in recent years, according to Ken Springer, the CEO of Corporate Resolutions, Springer's business is on the upswing. 'Business has increased dramatically. I think we've almost doubled in size the last two or three years,' he said. Springer and his team conduct background checks, searching for resume fraud. The company also investigates money laundering, cyber threats, and embezzlement. Springer, a former FBI agent, works with a team of investigators at his offices in New York. 'We've been in business twenty-five years now, and with some of the newer schemes and with cyber fraud, I think we'll be in business for the next twenty-five years,' said Springer. The investigator said not much has changed since Bernie Madoff's Ponzi scheme cost investors billions of dollars. 'Going back to Madoff in '08, it hasn't stopped. We would have thought people would have learned their lesson. They haven't. It comes down to people not knowing enough about the people they are doing business with,' explained Springer.
More from Video
Amid the Selling, Here's the Big Question Now
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
One Tweet Pulls the Rug Out From Under the Indexes
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
A Technical Look at the New Dow Jones Industrial Average
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
Conagra Brands Looks Tastier After Its Upgrade to Buy
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Biogen Bulls Get a Lift From Quant Upgrade and Strengthening Charts
Breaking down an approach to the long side of this biotech stock.